Heplisav-B vs Engerix-B in Adults with Chronic Kidney Disease (CKD) HBV-17 Trial



Heplisav-B Vaccine versus Engerix-B Vaccine in Adults with CKD HBV-17 Trial: Design

Design

- Phase 3 randomized, observer-blinded, active controlled, trial to compare the safety and efficacy of 3 doses of Heplisav-B versus 4 double-doses of Engerix B in adults with chronic kidney disease (CKD)
- Participants (n = 521 randomized, 507 analyzed)
 - Ages: 18-75 years
 - Chronic kidney disease: GFR ≤45 mL/min/1.73 m² +/- hemodialysis
 - HBV vaccine naïve
 - Exclusions: HBV*, HIV, HCV, pregnancy or lactation, autoimmune or other clinically significant illness, immunosuppressed

Setting

Multiple centers in United States & Canada


Study End-Point

Seroprotection = anti-HBs level ≥10 mIU/mL



^{*}Any positive for HBsAg, anti-HBs, or anti-HB core

Heplisav-B Vaccine versus Engerix-B Vaccine in Adults with CKD HBV-17 Trial: Design




Vaccine Dosing

Heplisav-B: 0.5 mL dose (standard dose = 20 mcg) recombinant HBsAg at weeks 0, 4, and 24 **Engerix-B**: 1 mL dose (double dose = 40 mcg) recombinant HBsAg at weeks 0, 4, 8, and 24




Heplisav-B Vaccine versus Engerix-B Vaccine in Adults with CKD HBV-17 Trial: Results (anti-HBs ≥10 mIU/mL)






Heplisav-B Vaccine versus Engerix-B Vaccine in Adults with CKD HBV-17 Trial: Results (anti-HBs ≥10 mIU/mL)





Heplisav-B Vaccine versus Engerix-B Vaccine in Adults with CKD HBV-17 Trial: Results (anti-HBs ≥100 mIU/mL)





Heplisav-B Vaccine versus Engerix-B Vaccine in Adults with CKD HBV-17 Trial: Conclusions

Conclusions: "In chronic kidney disease patients, 3 doses of HBsAg-1018 induced significantly higher seroprotection, earlier seroprotection, and more durable seroprotection than 4 double doses of HBsAg-Eng."



This slide deck is from the University of Washington's Hepatitis B Online and Hepatitis C Online projects.

Hepatitis B Online www.hepatitisB.uw.edu

Hepatitis C Online www.hepatitisC.uw.edu

This project is funded by the Centers for Disease Control and Prevention (CDC)

Cooperative Agreement (CDC-RFA- PS21-2105)

